MindBio Therapeutics (XCNQ:MBIO) Gross-Profit-to-Asset % : 747.45% (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. MindBio Therapeutics's annualized Gross Profit for the quarter that ended in Mar. 2024 was C$1.54 Mil. MindBio Therapeutics's average Total Assets over the quarter that ended in Mar. 2024 was C$0.21 Mil. Therefore, MindBio Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 was 747.45%.

MindBio Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for MindBio Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics Gross-Profit-to-Asset % Chart

MindBio Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Gross-Profit-to-Asset %

MindBio Therapeutics Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Gross-Profit-to-Asset %	Get a 7-Day Free Trial					-	-	-	378.61	747.45

Competitive Comparison of MindBio Therapeutics's Gross-Profit-to-Asset %

For the Biotechnology subindustry, MindBio Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Gross-Profit-to-Asset % falls into.

MindBio Therapeutics Gross-Profit-to-Asset % Calculation

MindBio Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	0	/	( (1.453	+	0.6)	/ 2 )
	=	0	/	1.0265
	=	0.00 %

MindBio Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Mar. 2024 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	1.536	/	( (0.134	+	0.277)	/ 2 )
	=	1.536	/	0.2055
	=	747.45 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Mar. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

MindBio Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

MindBio Therapeutics (XCNQ:MBIO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

WF6:Germany

Address

91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000

Website

https://www.mindbiotherapeutics.com

MindBio Therapeutics Corp is pioneering clinical studies into the microdosing of psychedelic medicines to treat a range of medical conditions such as depression, anxiety, PTSD, panic disorder, chronic pain and opiate addictions. Its clinical trials microdosing of psychedelic medicines provide hope for sufferers of mental health conditions with new emerging treatment alternatives. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the activities of the company takes place in Australia.